CLNN.NASDAQClene INC

Form 4: Clene Inc. Director Alison Mosca Reports Acquisition of Stock Options

Sentiment:

Insider Transaction Report


๐Ÿ“‹All filings for Clene INC

Clene Inc. Director Alison Mosca has reported the acquisition of 9,484 stock options, with varying vesting schedules, under the company's Amended 2020 Stock Plan.

Summary

  • Alison Mosca, a Director of Clene Inc. (CLNN), acquired a total of 9,484 stock options on May 22, 2025.
  • One grant consists of 1,500 options with an exercise price of $2.45 per share, vesting in 12 equal monthly installments beginning June 22, 2025.
  • A separate grant includes 7,984 options, also at an exercise price of $2.45 per share, which vested immediately upon grant on May 22, 2025.
  • All options were granted under the Clene Inc. Amended 2020 Stock Plan and have an expiration date of May 21, 2035.

Sentiment

Score: 6

Explanation: Slightly positive as it indicates continued alignment of a director with the company's performance through equity grants, which is a standard practice.

Positives

  • The grant of stock options to a director aligns management's interests with shareholder value creation.
  • The immediate vesting of 7,984 options provides immediate equity exposure for the director.

Negatives

  • No negative information is presented in this Form 4 filing, which primarily reports insider transactions.

Risks

  • This Form 4 filing does not disclose specific risks to the company's operations or financial health.

Future Outlook

The vesting schedule for 1,500 options indicates a future commitment and alignment of the director with the company's long-term performance over the next 12 months.

Industry Context

Insider transactions, such as the grant of stock options, are a common form of executive and director compensation across various industries, aiming to incentivize long-term performance and align interests with shareholders.

Comparison to Industry Standards

  • This Form 4 reports a standard equity grant to a director, a common practice in corporate governance across publicly traded companies, including those in the biotechnology or pharmaceutical sectors like Clene Inc. Specific comparable companies or projects are not detailed in this filing, as it focuses solely on an individual's transaction.

Corporate Governance

Change TypeDescriptionEffective DateImpact Assessment
Equity Plan UtilizationThe stock options were granted under the Clene Inc. Amended 2020 Stock Plan, indicating the ongoing use of this established equity compensation framework.05/22/2025Reinforces the company's existing compensation structure designed to incentivize directors and align their interests with long-term shareholder value.

Related Party Transactions

  • The grant of stock options to Alison Mosca, a director of Clene Inc., constitutes a related party transaction as it involves compensation from the company to an insider.

Stakeholder Impact

  • Shareholders: The transaction aligns the director's interests with shareholders through equity ownership, potentially encouraging decisions that enhance long-term stock value.
  • Employees: No direct impact on general employees is indicated by this specific filing.

Next Steps

  • Continued vesting of 1,500 stock options over the next 12 months.

Key Dates

DateDescription
05/22/2025Date of transaction and grant of stock options to Alison Mosca.
06/22/2025Start date for monthly vesting of 1,500 stock options.
05/21/2035Expiration date for all granted stock options.

Keywords

Clene Inc., CLNN, Form 4, Stock Options, Insider Transaction, Beneficial Ownership, Director Compensation, Equity Grant, Vesting Schedule

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.